News
UK-based health tech company launches home testing platform
The platform aims to convert complex biomarker results into easy-to-understand health scores
The UK-based health tech company Forth has launched an “advanced” home testing platform capable of converting biomarker results into health scores.
Health Coach, Forth says, is a significant advancement in the interpretation of blood test results, offering better insight into “personalised health”.
The company claims the platform “translates” biomarker scores into health scores with identification of key health areas for the individual to improve.
“HealthCoach is Forth’s most advanced integration tool yet,” said Dr Tom Phillips, head of clinical services at Forth.
“We have been working hard to design a system that understands your body’s systems don’t work in isolation and are integrated networks that rely on each other for optimal function. The platform understands this and provides individual feedback and targets based on your profile and results.
“Health Coach then guides you on ways to improve your biomarker landscape and ultimately lead to better health and wellbeing.”
Phillips said: “We have paid particular attention to developing a platform which personalises advice for women who may be taking hormone treatment and our algorithms also take information on a woman’s menstrual cycle.”
The ten categories that Health Coach has developed include heart, hormone, metabolic, nutrition, bone and muscle and mental health. The platform calculates a score for each area and then pinpoints the biomarkers the user should concentrate on.
Sarah Bolt, co-founder and CEO at Forth, said: “Having been one of the pioneers in the home testing sector, we wanted to use our years of experience to develop the next generation technology platform that really helps people to gain a deeper understanding of their health and also supports them in improving it.
“Our goal is simple: to not only improve health but to extend health span, enabling our customers to enjoy richer, fuller and longer lives.”
The launch of Health Coach, Bolt said, comes off the back of 18 months development and testing with Forth’s clinical and technical experts.
“This advancement comes at a time when the UK’s health resources are under increasing strain whilst health disorders are on the rise particularly with obesity levels and an ageing population,” she added.
To receive the Femtech World newsletter, sign up here.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Fertility2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







3 Comments